Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Rationale: Clinical variables associated with shortened survival in patients with advanced-stage cystic fibrosis (CF) are not included in the lung allocation score (LAS). Objectives: To identify variables associated with wait-list and post-transplant mortality for CF lung transplant candidates using a novel database and to analyze the impact of including new CF-specific variables in the LAS system. Methods: A deterministic matching algorithm identified patients from the Scientific Registry of Transplant Recipients and the Cystic Fibrosis Foundation Patient Registry. LAS wait-list and post-transplant survival models were recalculated using CF-specific variables. This multicenter, retrospective, population-based study of all lung transplant wait-list candidates aged 12 years or older from January 1, 2011, to December 31, 2014, included 9,043 patients on the lung transplant waiting list and 6,110 lung transplant recipients between 2011 and 2014, comprising 1,020 and 677 with CF, respectively. Measurements and Main Results: Measured outcomes were changes in LAS and lung allocation rank. For CF candidates, any Burkholderia sp. (hazard ratio [HR], 2.8; 95% confidence interval [CI], 1.2–6.6), 29–42 days hospitalized (HR 2.8; CI 1.3–5.9), massive hemoptysis (HR 2.1; CI 1.1–3.9), and relative drop in FEV1 ≥30% over 12 months (HR 1.7; CI 1.0–2.8) increased wait-list mortality risk; pulmonary exacerbation time 15–28 days (1.8; 1.1–2.9) increased post-transplant mortality risk. A relative drop in FEV1 ≥10% in chronic obstructive pulmonary disease (COPD) candidates was associated with increased wait-list mortality risk (HR 2.6; CI 1.2–5.4). Variability in LAS score and rank increased in patients with CF. Priority for transplant increased for COPD candidates. Access did not change for other diagnosis groups. Conclusions: Adding CF-specific variables improved discrimination among wait-listed CF candidates and benefited COPD candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Independent of FEV1, the following factors have been associated with increasing risk of disease progression or death: frequent or severe exacerbations, massive hemoptysis requiring bronchial artery embolization, pneumothorax, malnutrition, low six-minute walk distance, and younger age upon development of advanced disease.(247, 252–260)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [247]
In the citing paper
“Additional risk factors for mortality in those with severely compromised lung function include FEV1< 25% predicted, rapid decline in FEV1, PaCO2 > 50mmHg, impaired functional status, and pulmonary hypertension. (244, 246–251)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [247]
In the citing paper
“Infection or colonization with multi-drug resistant organisms including Burkholderia cepacia complex, Pseudomonas aeruginosa, and nontuberculous mycobacteria (M. abscessus in particular) have been shown to increase the rate of lung function decline or death without transplant in advanced CF.(245, 247, 254, 258, 262)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [247]
Citations
Cites
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015 · cited 1×
“Moreover, FEV1 is known to be a risk factor for death among non-CF lung transplant patient populations (12, 13).”
BackgroundDyspnea Is a Better Predictor of 5-Year Survival Than Airway Obstruction in Patients With COPD
Nishimura, K., Izumi, T., Tsukino, M., & Oga, T. (2002) · Chest · doi:10.1378/chest.121.5.1434 · Cited by 996
Prediction of mortality in patients with cystic fibrosis
Kerem, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261804 · Cited by 993
Prognosis in Chronic Obstructive Pulmonary Disease 1– 3
Anthonisen, N. R., Wright, E. C., Hodgkin, J. E., & IPPB Trial Group (1986) · American Review of Respiratory Disease · doi:10.1164/arrd.1986.133.1.14 · Cited by 777
Development of the New Lung Allocation System in the United States
Egan, T. M., Murray, S., Bustami, R. T., Shearon, T. H., McCullough, K. P., Edwards, L. B., Coke, M. A., Garrity, E. R., Sweet, S. C., Heiney, D. A., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01276.x · Cited by 767 · cited 3×
“Conclusions The LAS was developed with the goal of allocating organs to candidates at the greatest risk of death and most likely to experience a survival benefit with transplant (3).”
BackgroundMethodInfluentialPredictive 5-year survivorship model of cystic fibrosis
Liou, T. G., Adler, F. R., FitzSimmons, S. C., Cahill, B. C., Hibbs, J. R., & Marshall, B. C. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.345 · Cited by 749
Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation
Sanders, D. B., Bittner, R. C. L., Rosenfeld, M., Hoffman, L. R., Redding, G. J., & Goss, C. H. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1421oc · Cited by 519
Knapp, E. A., Fink, A. K., Goss, C. H., Sewall, A., Ostrenga, J., Dowd, C., Elbert, A., Petren, K. M., & Marshall, B. C. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201511-781oc · Cited by 346 · cited 1×
“The CFFPR is estimated to include approximately 81–84% of people with CF in the United States and included 29,497 individuals in 2016 (1, 9).”
BackgroundSelf-citationLeppke, S., Leighton, T., Zaun, D., Chen, S.-C., Skeans, M., Israni, A. K., Snyder, J. J., & Kasiske, B. L. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.01.002 · Cited by 307 · cited 1×
“We created a database that matched patients found in both the SRTR and CFFPR databases (8, 10).”
MethodSelf-citationDeveloping cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
Mayer-Hamblett, N., Rosenfeld, M., Emerson, J., Goss, C. H., & Aitken, M. L. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200202-087oc · Cited by 269
ARIS, R. M., ROUTH, J. C., LiPUMA, J. J., HEATH, D. G., & GILLIGAN, P. H. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.11.2107022 · Cited by 256
Infection with Burkholderia cepacia in Cystic Fibrosis: Outcome Following Lung Transplantation
CHAPARRO, C., MAURER, J., GUTIERREZ, C., KRAJDEN, M., CHAN, C., WINTON, T., KESHAVJEE, S., SCAVUZZO, M., TULLIS, E., HUTCHEON, M., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.1.9811076 · Cited by 232
A contemporary survival analysis of individuals with cystic fibrosis: a cohort study
Stephenson, A. L., Tom, M., Berthiaume, Y., Singer, L. G., Aaron, S. D., Whitmore, G. A., & Stanojevic, S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00119714 · Cited by 185
Impact of Burkholderia Infection on Lung Transplantation in Cystic Fibrosis
Murray, S., Charbeneau, J., Marshall, B. C., & LiPuma, J. J. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1834oc · Cited by 177 · cited 1×
“We were unable to analyze its effect on survival, owing to a small number of patients (n=4) with documented infection or colonization (28, 29).”
BackgroundAlexander, B. D., Petzold, E. W., Reller, L. B., Palmer, S. M., Davis, R. D., Woods, C. W., & LiPuma, J. J. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02186.x · Cited by 177 · cited 1×
“We were unable to analyze its effect on survival, owing to a small number of patients (n=4) with documented infection or colonization (28, 29).”
BackgroundOPTN/SRTR 2016 annual data report: lung
Valapour, M., Lehr, C. J., Skeans, M. A., Smith, J. M., Carrico, R., Uccellini, K., Lehman, R., Robinson, A., Israni, A. K., Snyder, J. J., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14562 · Cited by 163 · cited 1×
“lung transplant waiting list, and lack of the FEV1 variable has long been a criticism of the LAS (30).”
BackgroundSelf-citationDe Soyza, A., McDowell, A., Archer, L., Dark, J. H., Elborn, S. J., Mahenthiralingam, E., Gould, K., & Corris, P. A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06808-8 · Cited by 158
Definitions, Epidemiology, Pathophysiology, Diagnosis, and Staging
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm/152.5_pt_2.s78 · Cited by 142
Survival Benefit of Lung Transplant for Cystic Fibrosis since Lung Allocation Score Implementation
Thabut, G., Christie, J. D., Mal, H., Fournier, M., Brugière, O., Leseche, G., Castier, Y., & Rizopoulos, D. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201303-0429oc · Cited by 139
Stephenson, A. L., Sykes, J., Berthiaume, Y., Singer, L. G., Aaron, S. D., Whitmore, G. A., & Stanojevic, S. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.05.003 · Cited by 102
Outcome of Patients with Cystic Fibrosis Awaiting Lung Transplantation
VIZZA, C. D., YUSEN, R. D., LYNCH, J. P., FEDELE, F., ALEXANDER PATTERSON, G., & TRULOCK, E. P. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9910102 · Cited by 97
Ramos, K. J., Quon, B. S., Heltshe, S. L., Mayer-Hamblett, N., Lease, E. D., Aitken, M. L., Weiss, N. S., & Goss, C. H. (2017) · Chest · doi:10.1016/j.chest.2017.01.019 · Cited by 95 · cited 2×
“We hypothesized that adding CFFPR variables would improve the LAS calculation to better differentiate CF candidates with the highest risk of mortality on the transplant waiting list and the best chance of survival after transplant (2).”
BackgroundA statistical model to predict one-year risk of death in patients with cystic fibrosis
Aaron, S. D., Stephenson, A. L., Cameron, D. W., & Whitmore, G. A. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.12.010 · Cited by 78
Physical activity and longitudinal change in 6-min walk distance in COPD patients
Frisk, B., Espehaug, B., Hardie, J. A., Strand, L. I., Moe‐Nilssen, R., Eagan, T., Bakke, P. S., & Thorsen, E. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.09.004 · Cited by 29
Outcomes following bronchial artery embolisation for haemoptysis in cystic fibrosis
Flight, W. G., Barry, P. J., Bright-Thomas, R. J., Butterfield, S., Ashleigh, R., & Jones, A. M. (2017) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-017-1626-0 · Cited by 28 · cited 1×
“Massive hemoptysis is also known to be associated with significant morbidity and mortality for patients with CF with end-stage lung disease and has not historically been included in transplant registries (19, 20).”
BackgroundSanders, D. B., Zhao, Q., Li, Z., & Farrell, P. M. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23765 · Cited by 18
Including Cystic-Fibrosis-Specific Variables Improves Accuracy of the Lung Allocation Score
Lehr, C. J., Skeans, M. A., Dasenbrook, E. C., Faro, A., Fink, A. K., Fernandez, G. S., & Valapour, M. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.01.854 · Cited by 1 · cited 1×
“Some of the results of these studies have been reported previously in the form of an abstract (11).”
Self-citation
Research works printed but not linked: 3
- Dasenbrook, 2017, Addition of FEV1 drop to LAS may improve access of CF patients to transplant: analysis of the SRTR and US CF Foundation patient registries [abstract], Am J Transplant, 17, 262
- Dasenbrook, 2016, Description of a novel database: merging the US CF Patient Registry with the Scientific Registry of Transplant Recipients [abstract], Pediatr Pulmonol, 51, 377
- Traver, 1979, Predictors of mortality in chronic obstructive pulmonary disease: a 15-year follow-up study, Am Rev Respir Dis, 119, 895
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
“…mycobacteria ( M. abscessus in particular) have been shown to increase the rate of lung function decline or death without transplant in advanced CF. 245,247,254,258,262 Implications of B. cenoce-pacia, M. abscessus , or L. prolificans are described above (infectious disease risk factors).”
BackgroundSelf-citationESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis
Wilschanski, M. A., Munck, À., Carrión‐Jaramillo, E., Cipolli, M., Collins, S., Colombo, C., Declercq, D., Hatziagorou, E., Hulst, J. M., Kalnins, D., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.12.017 · Cited by 150
Burgel, P., Southern, K. W., Addy, C., Battezzati, A., Berry, C. A., Bouchara, J., Brokaar, E. J., Brown, A. W., Azevedo, P., Durieu, I., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.01.005 · Cited by 116
“…the subject of consensus documents [193] and practical guidelines [194], recognizing the specific needs of people with CF. Determining the optimal timing for lung transplantation remains difficult and may differ between countries based on health system and organ allocation differences [195,196].”
BackgroundAcute Pulmonary Exacerbations in Cystic Fibrosis
Goss, C. H. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1697975 · Cited by 109
Organ Transplantation for Cystic Fibrosis
Morrell, M. R., Kiel, S., & Pilewski, J. M. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399554 · Cited by 32
Metadata
- Authors
- Lehr, C. J., Skeans, M., Dasenbrook, E., Fink, A., Fernandez, G., Faro, A., & Valapour, M.
- Affiliations
- Cleveland Clinic (US)
- Hennepin Healthcare Research Institute (US)
- Cystic Fibrosis Foundation (US)
- Corresponding author
- Valapour, Maryam
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10
- Volume
- 200
- Issue
- 8
- Pages
- 1013-1021
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2950878989
- Semantic Scholar
- 16938c35a47167c479d7337b7a5902a6fecaadd0
- Cited by
- 35
- References
- 27
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 8 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 4
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cystic Fibrosis Foundation
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
- Keywords
- lung allocation score, cystic fibrosis, chronic obstructive pulmonary disease, lung transplantation, post-transplant mortality, Burkholderia, pulmonary exacerbations, FEV1 decline, transplant prioritization, clinical risk factors
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Algorithms, Child, Cystic Fibrosis, Female, Humans, Male, Middle Aged, Tissue and Organ Procurement, Retrospective Studies, Severity of Illness Index, Waiting Lists, Reproducibility of Results, Proportional Hazards Models, Lung Transplantation, Practice Guidelines as Topic, Patient Selection, Pulmonary Disease, Chronic Obstructive, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.